Processing

Please wait...

Settings

Settings

1. WO2000040225 - INHIBITION OF TNF ACTIVITY

Publication Number WO/2000/040225
Publication Date 13.07.2000
International Application No. PCT/IL1999/000709
International Filing Date 30.12.1999
IPC
A61K 31/727 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
726Glycosaminoglycans, i.e. mucopolysaccharides
727Heparin; Heparan
A61K 38/17 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
CPC
A61K 31/727
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
726Glycosaminoglycans, i.e. mucopolysaccharides
727Heparin; Heparan
A61K 38/1793
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
177Receptors; Cell surface antigens; Cell surface determinants
1793for cytokines; for lymphokines; for interferons
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
Y10S 514/825
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
10TECHNICAL SUBJECTS COVERED BY FORMER USPC
STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
514Drug, bio-affecting and body treating compositions
825Arthritis
Applicants
  • APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. [NL/NL]; Pietermaai 15 Curacao, AN (AllExceptUS)
  • ADERKA, Dan [IL/IL]; IL (UsOnly)
  • ESHED (ENGLENDER), Talma [IL/IL]; IL (UsOnly)
Inventors
  • ADERKA, Dan; IL
  • ESHED (ENGLENDER), Talma; IL
Agents
  • EINAV, Henry; Interpharm Laboratories Ltd. Science-based Industrial Park Kiryat Weizmann 76110 Ness-Ziona, IL
Priority Data
12785130.12.1998IL
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) INHIBITION OF TNF ACTIVITY
(FR) INHIBITION DE L'ACTIVITE DU TNF
Abstract
(EN)
The bioactivity of TNF is inhibited by administering heparin or a derivative thereof along with a soluble TNF receptor. The heparin or derivative thereof can be administered simultaneously with the soluble TNF receptor, either in separate compositions or in compositions containing both heparin or a derivative thereof and at least one soluble TNF receptor. The heparin or derivative may also be administered without the soluble TNF receptor and still effect some amount of inhibition of TNF bioactivity.
(FR)
La bioactivité du TNF est inhibée par administration de l'héparine ou d'un dérivé de l'héparine en combinaison avec un récepteur du TNF soluble. L'héparine ou son dérivé peut être administrée simultanément avec le récepteur du TNF soluble, soit dans des compositions distinctes, soit dans des compositions contenant l'héparine ou un dérivé de l'héparine et au moins un récepteur du TNF soluble. L'héparine ou son dérivé peut également être administrée sans le récepteur du TNF soluble et inhiber dans une certaine mesure la bioactivité du TNF.
Latest bibliographic data on file with the International Bureau